AU2001254624A1 - Human coagulation factor vii variants - Google Patents

Human coagulation factor vii variants

Info

Publication number
AU2001254624A1
AU2001254624A1 AU2001254624A AU5462401A AU2001254624A1 AU 2001254624 A1 AU2001254624 A1 AU 2001254624A1 AU 2001254624 A AU2001254624 A AU 2001254624A AU 5462401 A AU5462401 A AU 5462401A AU 2001254624 A1 AU2001254624 A1 AU 2001254624A1
Authority
AU
Australia
Prior art keywords
coagulation factor
human coagulation
variants
factor vii
vii variants
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001254624A
Inventor
Ole Hvilsted Olsen
Egon Persson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2001254624A1 publication Critical patent/AU2001254624A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)

Abstract

The present invention relates to novel human coagulation Factor VIIa variants having coagulant activity as well as nucleic acid constructs encoding such variants, vectors and host cells comprising and expressing the nucleic acid, pharmaceutical compositions, uses and methods of treatment. The variants have been modified in position 305 or position 374 in native human coagulation Factor VII.
AU2001254624A 2000-05-03 2001-05-01 Human coagulation factor vii variants Abandoned AU2001254624A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200000734 2000-05-03
DKPA200000734 2000-05-03
DKPA200001360 2000-09-13
DKPA200001360 2000-09-13
PCT/DK2001/000294 WO2001083725A1 (en) 2000-05-03 2001-05-01 Human coagulation factor vii variants

Publications (1)

Publication Number Publication Date
AU2001254624A1 true AU2001254624A1 (en) 2001-11-12

Family

ID=26068821

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001254624A Abandoned AU2001254624A1 (en) 2000-05-03 2001-05-01 Human coagulation factor vii variants

Country Status (6)

Country Link
EP (1) EP1282693B1 (en)
JP (2) JP4455802B2 (en)
AT (1) ATE485371T1 (en)
AU (1) AU2001254624A1 (en)
DE (1) DE60143292D1 (en)
WO (1) WO2001083725A1 (en)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
DE60138364D1 (en) 2000-02-11 2009-05-28 Bayer Healthcare Llc CLEANING FACTOR VII OR VIIA CONJUGATE
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6905683B2 (en) 2000-05-03 2005-06-14 Novo Nordisk Healthcare A/G Human coagulation factor VII variants
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
RU2326126C2 (en) 2000-09-13 2008-06-10 Ново Нордиск Хелт Кэр Аг Polypeptyde of hemostasis factor vii, production and application
HUP0301246A3 (en) * 2000-09-13 2005-12-28 Novo Nordisk Healthcare Ag Human coagulation factor vii variants
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
US7235638B2 (en) 2001-03-22 2007-06-26 Novo Nordisk Healthcare A/G Coagulation factor VII derivatives
ATE532858T1 (en) * 2001-09-27 2011-11-15 Novo Nordisk Healthcare Ag HUMAN CLOTTING FACTOR VII POLYPEPTIDES
US7052868B2 (en) 2001-09-27 2006-05-30 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
JP2005512524A (en) * 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Human coagulation factor VII polypeptide
US6960657B2 (en) 2001-11-02 2005-11-01 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
WO2003039590A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and aprotinin polypeptides
US7291587B2 (en) 2001-11-09 2007-11-06 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides
JP2005510514A (en) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Pharmaceutical compositions comprising a Factor VII polypeptide and a PAI-1 polypeptide
WO2003039585A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and protein c inhibitors
JP2005510513A (en) * 2001-11-09 2005-04-21 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Pharmaceutical compositions comprising factor VII polypeptide and TAFI polypeptide
US7078479B2 (en) 2001-11-09 2006-07-18 Novo Nordisk Healthcare A/G Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides
WO2003039588A1 (en) * 2001-11-09 2003-05-15 Novo Nordisk Health Care Ag Pharmaceutical composition comprising factor vii polypeptides and tissue plasminogen inhibitors
EP1446154A1 (en) * 2001-11-09 2004-08-18 Novo Nordisk Health Care AG Pharmaceutical composition comprising factor vii polypeptides and alpha2 -antiplasmin polypeptides
BR0215216A (en) 2001-12-21 2004-11-16 Novo Nordisk Healthcare Ag Liquid aqueous composition, method for preparing a liquid aqueous composition of a factor vii polypeptide, use of a liquid aqueous composition, and method for treating a factor vii response syndrome
NZ536340A (en) 2002-04-30 2006-09-29 Maxygen Holdings Ltd Factor VII or VIIa polypeptide variants with N-glycosylation
DK1517710T3 (en) 2002-06-21 2011-07-18 Novo Nordisk Healthcare Ag Pegylated factor VII glycoforms
ES2523655T5 (en) 2002-06-21 2018-04-23 Novo Nordisk Health Care Ag Solid stabilized compositions of Factor VIIa polypeptides
US6933136B2 (en) 2002-09-20 2005-08-23 Novo Nordisk A/S Method for making recombinant proteins
JP4597678B2 (en) 2002-09-25 2010-12-15 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Human coagulation factor VII polypeptide
US6911323B2 (en) 2002-09-25 2005-06-28 Novo Nordisk Healthcare A/G Human coagulation factor VII polypeptides
CN101818138A (en) 2003-03-18 2010-09-01 诺和诺德医疗保健公司 Method for the production of GLA-residue containing serine proteases
AU2004221761B2 (en) 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
PT1644504E (en) 2003-06-19 2010-03-22 Bayer Healthcare Llc Factor vii or viia gla domain variants
ATE547114T1 (en) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag LIQUID COMPOSITIONS OF FACTOR VII POLYPEPTIDES
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
CN101870729A (en) * 2003-09-09 2010-10-27 诺和诺德医疗保健公司 Coagulation factor vii polypeptides
WO2005032581A2 (en) 2003-10-07 2005-04-14 Novo Nordisk Health Care Ag Hybrid molecules having factor vii/viia activity
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
ES2507091T3 (en) 2003-12-01 2014-10-14 Novo Nordisk Health Care Ag Nanofiltration of factor VII solutions to eliminate viruses
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
EP2311437A1 (en) 2003-12-19 2011-04-20 Novo Nordisk Health Care AG Stabilised compositions of factor VII polypeptides
EP1708755B1 (en) 2004-01-21 2012-03-21 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
WO2005075635A2 (en) * 2004-02-03 2005-08-18 Novo Nordisk Health Care Ag Coagulation factor vii/viia variants lacking a functional lipid membrane binding domain
ES2572779T3 (en) 2004-10-29 2016-06-02 Ratiopharm Gmbh Remodeling and glucopegilation of Fibroblast Growth Factor (FGF)
EP2360171A1 (en) 2004-12-23 2011-08-24 Novo Nordisk Health Care AG Reduction of the content of protein contaminants in compositions comprising a vitamin K-dependent protein of interest
ES2449195T3 (en) 2005-01-10 2014-03-18 Ratiopharm Gmbh Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5335422B2 (en) 2005-06-17 2013-11-06 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Selective reduction and derivatization of engineered proteins containing at least one unnatural cysteine
EP1904528B1 (en) 2005-07-13 2012-10-31 Novo Nordisk Health Care AG Host cell protein knock-out cells for production of therapeutic proteins
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007026021A1 (en) 2005-09-01 2007-03-08 Novo Nordisk Health Care Ag Hydrophobic interaction chromatography purification of factor vii polypeptides
EP1926817A2 (en) 2005-09-14 2008-06-04 Novo Nordisk Health Care AG Human coagulation factor vii polypeptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
EP2059527B1 (en) 2006-09-01 2014-12-03 Novo Nordisk Health Care AG Modified glycoproteins
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As Methods for the purification of polypeptide conjugates
BRPI0720282B8 (en) 2006-12-15 2021-05-25 Baxalta GmbH protein construction, pharmaceutical composition, and kit
CA2682897C (en) 2007-04-03 2016-11-22 Biogenerix Ag Methods of treatment using glycopegylated g-csf
MX2009010997A (en) 2007-04-13 2009-11-02 Catalyst Biosciences Inc Modified factor vii polypetides and uses thereof.
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
ES2644089T3 (en) 2007-12-27 2017-11-27 Baxalta GmbH Cell culture procedures
US20130189239A1 (en) 2008-02-27 2013-07-25 Novo Nordisk A/S Conjugated Factor VIII Molecules
TWI465247B (en) 2008-04-11 2014-12-21 Catalyst Biosciences Inc Factor vii polypeptides that are modified and uses thereof
AU2010258752B2 (en) 2009-06-09 2015-07-09 Prolong Pharmaceuticals, LLC Hemoglobin compositions
FR2947181B1 (en) * 2009-06-26 2012-05-04 Lfb Biotechnologies FACTOR VII COMPOSITION
RU2744370C2 (en) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Blood coagulation protein conjugates
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2597954T3 (en) 2009-07-27 2017-01-24 Baxalta GmbH Blood coagulation protein conjugates
EP2459226B1 (en) 2009-07-27 2016-06-29 Lipoxen Technologies Limited Glycopolysialylation of proteins other than blood coagulation proteins
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN103080135B (en) 2010-06-30 2017-06-13 诺沃—诺迪斯克有限公司 The antibody of tissue factor approach restrainer can be specifically bound
ES2800983T3 (en) 2010-12-22 2021-01-07 Baxalta GmbH Materials and methods for conjugating a water-soluble fatty acid derivative with a protein
JP6309273B2 (en) 2011-03-02 2018-04-11 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Targeting clotting factors to TLT-1 on activated platelets
WO2012170969A2 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
EP2554161A1 (en) 2011-08-02 2013-02-06 LFB Biotechnologies Pharmaceutical composition comprising factor VII encapsulated in micelles
CN104717973A (en) 2012-10-10 2015-06-17 诺和诺德保健Ag（股份有限公司） Liquid pharmaceutical composition of factor VII polypeptide
JP2015533152A (en) 2012-10-15 2015-11-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー Factor VII conjugate
DK3402537T3 (en) 2016-01-15 2021-03-29 Rigshospitalet Quantitative PET imaging of tissue factor expression using 18-F labeled, active position-inhibited factor VII
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII

Also Published As

Publication number Publication date
DE60143292D1 (en) 2010-12-02
JP4456165B2 (en) 2010-04-28
JP4455802B2 (en) 2010-04-21
JP2003531607A (en) 2003-10-28
EP1282693A1 (en) 2003-02-12
EP1282693B1 (en) 2010-10-20
JP2009060902A (en) 2009-03-26
WO2001083725A1 (en) 2001-11-08
ATE485371T1 (en) 2010-11-15

Similar Documents

Publication Publication Date Title
AU2001254624A1 (en) Human coagulation factor vii variants
MXPA03001984A (en) Human coagulation factor vii variants.
AU2003266214A1 (en) Human coagulation factor vii polypeptides
WO2002022776A3 (en) Human coagulation factor vii variants
TW200407425A (en) Human coagulation factor VII polypeptides
HK1084404A1 (en) Muteins of tear lipocalin
HUP0401124A2 (en) Coagulation factor vii derivatives
DK0910647T3 (en) Human DNase in hyperactive variants
MXPA03002218A (en) Antimicrobial peptides and methods of use.
WO2001092308A3 (en) Cystine-knot polypeptides: cloaked-2 molecules and uses thereof
WO2005123916A3 (en) Glycosylation-disrupted factor vii variants
MXPA03001673A (en) Lactic acid bacteria capable of reducing an individual s tendency to develop allergic reactions.
WO2003030821A3 (en) Albumin fusion proteins
WO2000053776A3 (en) Human kallikrein-like genes
EP2392655A3 (en) Coagulation factor VII polypeptides
WO2005024006A8 (en) Coagulation factor VII polypeptides
UA84831C2 (en) Coagulation factor vii derivatives
UA81601C2 (en) Normal;heading 1;heading 2;FACTOR VII POLYPEPTIDES FOR PREVENTING FORMATION OF INHIBITORS IN SUBJECTS WITH HAEMOPHILIA
ATE230027T1 (en) HUMAN DNASE I VARIANTS
WO2002086067A3 (en) Mycobacterial sulfation pathway proteins and methods of use thereof
WO2003040119A8 (en) Angiogenesis inhibitors
WO2002063013A3 (en) Human acid phosphatase gene
AU9683401A (en) Flea peritrophin nucleic acid molecules, proteins and uses thereof
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same
WO2001092301A3 (en) Placc, a novel human c-c chemokine isolated from placenta